Search research articles
Contact Us
Filters
Showing results (51-60 of 71) with videos related to
Page
of 8
Sort By:
Journal of Affective Disorders
|
August 8, 2025
Blood-based biomarkers in ketamine treatment: A blueprint for translational drug development in mood disorders
Alan C Courtes, Gregory H Jones, Ioline D Henter, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
|
August 12, 2016
Genetic Studies on the Tripartite Glutamate Synapse in the Pathophysiology and Therapeutics of Mood Disorders
Rafael T de Sousa, Alexandre A Loch, André F Carvalho, et al.
Drug Discovery Today
|
February 9, 2023
Inflammation, stress and depression: An exploration of ketamine's therapeutic profile
Jenessa N Johnston, Maximillian S Greenwald, Ioline D Henter, et al.
Schizophrenia Research
|
August 23, 2012
Binding of a tritiated inverse agonist to cannabinoid CB1 receptors is increased in patients with schizophrenia
Kimberly J Jenko, Jussi Hirvonen, Ioline D Henter, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
|
February 3, 2012
Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study
Lobna Ibrahim, Nancy Diazgranados, Jose Franco-Chaves, et al.
Journal of Affective Disorders
|
August 30, 2024
The effect of intranasal (R,S)-ketamine on symptoms of fatigue in severe major depressive disorder or bipolar depression with and without comorbid alcohol use disorder: Results from a randomized, double-blind, placebo-controlled trial
Rodrigo Machado-Vieira, Gregory H Jones, Alan C Courtes, et al.
Revista De Psiquiatria Clinica
|
June 18, 2015
Biomarkers in mood disorders research: developing new and improved therapeutics
Mark J Niciu, Daniel C Mathews, Dawn F Ionescu, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
June 1, 2022
Cyclooxygenases as Potential PET Imaging Biomarkers to Explore Neuroinflammation in Dementia
Bruny V Kenou, Lester S Manly, Sara B Rubovits, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
January 14, 2022
In Vivo Evaluation of 6 Analogs of <sup>11</sup>C-ER176 as Candidate <sup>18</sup>F-Labeled Radioligands for 18-kDa Translocator Protein
Jae-Hoon Lee, Fabrice G Siméon, Jeih-San Liow, et al.
Neuroscience and Biobehavioral Reviews
|
January 4, 2025
Temporal dynamics of affective scene processing in the healthy adult human brain
Abigail O Vogeley, Alicia A Livinski, Shahaboddin Dabaghi Varnosfaderani, et al.
Page
of 8
Search research articles
Search
Showing results (51-60 of 71) with videos related to
Sort By:
Page
of 8
Journal of Affective Disorders
|
August 8, 2025
Blood-based biomarkers in ketamine treatment: A blueprint for translational drug development in mood disorders
Alan C Courtes, Gregory H Jones, Ioline D Henter, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
|
August 12, 2016
Genetic Studies on the Tripartite Glutamate Synapse in the Pathophysiology and Therapeutics of Mood Disorders
Rafael T de Sousa, Alexandre A Loch, André F Carvalho, et al.
Drug Discovery Today
|
February 9, 2023
Inflammation, stress and depression: An exploration of ketamine's therapeutic profile
Jenessa N Johnston, Maximillian S Greenwald, Ioline D Henter, et al.
Schizophrenia Research
|
August 23, 2012
Binding of a tritiated inverse agonist to cannabinoid CB1 receptors is increased in patients with schizophrenia
Kimberly J Jenko, Jussi Hirvonen, Ioline D Henter, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
|
February 3, 2012
Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study
Lobna Ibrahim, Nancy Diazgranados, Jose Franco-Chaves, et al.
Journal of Affective Disorders
|
August 30, 2024
The effect of intranasal (R,S)-ketamine on symptoms of fatigue in severe major depressive disorder or bipolar depression with and without comorbid alcohol use disorder: Results from a randomized, double-blind, placebo-controlled trial
Rodrigo Machado-Vieira, Gregory H Jones, Alan C Courtes, et al.
Revista De Psiquiatria Clinica
|
June 18, 2015
Biomarkers in mood disorders research: developing new and improved therapeutics
Mark J Niciu, Daniel C Mathews, Dawn F Ionescu, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
June 1, 2022
Cyclooxygenases as Potential PET Imaging Biomarkers to Explore Neuroinflammation in Dementia
Bruny V Kenou, Lester S Manly, Sara B Rubovits, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
January 14, 2022
In Vivo Evaluation of 6 Analogs of <sup>11</sup>C-ER176 as Candidate <sup>18</sup>F-Labeled Radioligands for 18-kDa Translocator Protein
Jae-Hoon Lee, Fabrice G Siméon, Jeih-San Liow, et al.
Neuroscience and Biobehavioral Reviews
|
January 4, 2025
Temporal dynamics of affective scene processing in the healthy adult human brain
Abigail O Vogeley, Alicia A Livinski, Shahaboddin Dabaghi Varnosfaderani, et al.
Page
of 8